Effect of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients: a pilot study

Acta Ophthalmol. 2019 Feb;97(1):e133-e134. doi: 10.1111/aos.13865. Epub 2018 Sep 10.

Authors

Olivia Esteban^{1

2}, Francisco J Ascaso^{1

2}, Javier Mateo¹, Tania Calvo³, Julio Montoya^{2

3

4}, Eduardo Ruiz-Pesini^{2

3

4

5}

Affiliations

¹ Department of Ophthalmology, University Clinic Hospital "Lozano Blesa", Zaragoza, Spain.
² Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.
³ Department of Biochemistry, Molecular and Cell Biology, University of Zaragoza, Zaragoza, Spain.
⁴ Spanish Network for Biomedical Research in Rare Diseases (CIBERER), Zaragoza, Spain.
⁵ ARAID Foundation, Zaragoza, Spain.

PMID: 30203451
DOI: 10.1111/aos.13865

No abstract available

Publication types

Letter

MeSH terms

Aged
Angiogenesis Inhibitors / administration & dosage
DNA, Mitochondrial / drug effects*
Female
Humans
Intravitreal Injections
Male
Pilot Projects
Ranibizumab / administration & dosage*
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Wet Macular Degeneration / drug therapy*
Wet Macular Degeneration / genetics

Substances

Angiogenesis Inhibitors
DNA, Mitochondrial
Vascular Endothelial Growth Factor A
Ranibizumab